



09-11-03

CASE 4-20921B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL987587516US
Express Mail Label Number

9/9/03
Date of Deposit

Certificate

SEP 17 2003

of Correction

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PATENT 6,485,745 OF

Art Unit: 1614

WAGNER ET AL.

Examiner: Di Nola Baron, L.

ISSUED: NOVEMBER 26, 2002

APPLICATION NO: 09/920,159

FILED: NOVEMBER 26, 2002

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION UNDER CFR § 1.322

Sir:

Pursuant to 37 CFR 1.322, it is hereby respectfully requested that a Certificate of Correction be issued for United States Patent **6,485,745** containing the corrections set forth on the appended Form PTO 1050.

On the title page of the patent, in item (63), the **"Related U.S. Application Data"** was listed incorrectly. This area should read: **"Continuation of application No. 09/202,805, filed on May 7, 1999, now Pat. No. 6,294,197, which is a 371 of International Application PCT/EP97/03172, filed on June 18, 1997"**. This is supported by the first page of the Preliminary Amendment, dated August 1, 2001 (a copy is enclosed herewith), which was sent to the PTO with the filing papers.

Further review of the patent showed that in Column 1, there was an error in line 2 of the first paragraph under the title. The U.S. application number should read: **No. 09/202,805 not No. 09/204,805**. The first page of the Preliminary Amendment, date August 1, 2001 will support this.

SEP 17 2003

Also, Applicants noted that in Column 10, the word "**damage**" should be replaced by "**dosage**" after the word "**said**". The location of support is on the second page of the Preliminary Amendment, dated August 1, 2001 (copy of this page is enclosed herewith). New claim 28 (now renumbered claim 8) shows this to be correct.

Attached is a duplicate of Form PTO 1050, with at least one copy being suitable for printing.

Since the above errors are not ascribable to the patentees, no fee is believed to be necessitated by this Request for Certificate of Correction. However, in the event that a fee is required, the Commissioner is hereby authorized to charge said fee to Deposit Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-8020
GDF/dd



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36134

Encls: copy of first and second pages of Preliminary Amendment, dated August 1, 2001
Forms PTO 1050 (2)

Date: 9/9/03



Case: 4-20921B

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 6,485,745 *BL*
DATED: : November 26, 2002
INVENTOR(S) : WAGNER ET AL.

It is certified that there are errors in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page

Item (63) should read:

-- Related U.S. Application Data

(63) Continuation of application No. 09/202,805, filed on May 7, 1999, now Pat. No. 6,294,197, which is a 371 of International Application PCT/EP97/03172, filed on June 18, 1997.--

Column 1, line *5* of the first paragraph under the title should read:

-- No. 09/202,805, filed May 7, 1999, now U.S. Pat. No. *6,294,197*

Column 10, line *27* of claim *11* should read:

-- compressed solid dosage form, and wherein said dosage --

MAILING ADDRESS OF SENDER:
Diane P. Tso
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7947

PATENT NO. 6,485,745

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,485,745 B1
DATED : November 26, 2002
INVENTOR(S) : Wagner et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,

Item [63], should read:

-- Related U.S. Application Data

[63] Continuation of application No. 09/202,805, filed on May 7, 1999, now Pat. No. 6,294,197, which is a 371 of International Application PCT/EP97/03172, filed on June 18, 1997. --.

Column 1,

Line 5, should read: --No. 09/202,805, filed May 7, 1999, now U.S. Pat. No. 6,294,197 --.

Column 10,

Line 27, should read: -- compressed solid dosage form, and wherein said dosage --.

Signed and Sealed this

Twenty-fifth Day of November, 2003

A handwritten signature in black ink, appearing to read "James E. Rogan", with a horizontal line drawn underneath it.

JAMES E. ROGAN
Director of the United States Patent and Trademark Office